Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%
TT

TG Therapeutics, Inc. (TGTX)

NASDAQ • Healthcare

$66.12
+$3.41 (+5.4%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$62.64
Day Range$62.32 - $66.66
Avg. Volume (3M)2.1M
Market Cap$9.9B
P/E Ratio89.4
52 Week Range
$26.76$68.03

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$259.9M100%
Gross Profitminus cost of goods$217.8M84%
Operating Incomeminus R&D and overhead$85.8M33%
Net Incomeminus taxes and the rest$55.4M21%

In plain terms: out of every $100 in revenue, TG Therapeutics, Inc. keeps $21 as net profit.

Fundamentals & Financials

Revenue (TTM)
$897.7M
Net Income (TTM)
$106M
EPS (TTM)
$0.74
ROA (TTM)
6.66%
Current Ratio
4.5
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-39.1%Q2 2026$0.14
-83.6%Q3 2026$0.05
-2.6%Q4 2026$0.35

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -2.6%

TG Therapeutics’ third fiscal quarter of 2026 mixed a revenue beat with an EPS miss, as results reported November 9, 2026 showed revenue of $259.9 million topped the $245.5 million estimate (+5.9%) while EPS of $0.35 trailed the $0.37 estimate (-5%). Revenue rose ~61% year over year to about $259.9 million (up from about $161.7 million a year ago), reflecting a quarter driven by its therapy portfolio across oncology and immunology. Profitability remained elevated on a margin basis, with gross margin near 84% and operating margin around 33%, alongside gross profit of roughly $217.9 million and operating income of about $85.9 million. Below the operating line, net income fell ~86% year over year to about $55.5 million (down from roughly $390.9 million a year ago), and EPS declined ~86% from $2.43 a year ago to $0.35. The company generated operating cash flow of roughly $45.2 million during the quarter. For the next period, consensus calls for EPS of $0.45 on revenue of $269.5 million.

View full earnings history

About TG Therapeutics, Inc.

TG Therapeutics, Inc. is a commercial-stage biotechnology company listed on the NASDAQ as TGTX that develops and sells therapies for B-cell related cancers and autoimmune disorders. FY2025 revenue was $616.3 million. Its business centers on monoclonal antibodies, targeted oral inhibitors, and earlier licensed programs in immunology and oncology.

Name
TG Therapeutics, Inc.
CEO
Michael S. Weiss
Industry
Healthcare
Year Founded
1993
Employees
399

Today's Snapshot

AI-generated

The day ended with TGTX 5.4% higher at 66.12, outperforming a weaker sector. TGTX closed within 2.8% of its 52-week high of 68.03. Analyst Julien Nono-Womdim named TG Therapeutics a top pick.

Trading Volume

Below 10d avg (2.5M)

1.8M

vs S&P 500 Today

Strong Outperformance

+5.70%

Updated: November 18, 2026 at 21:14 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
TGTX is rated Strong Buy supported by constructive momentum and a bullish moving-average profile. The stock trades well above its short, medium and 200-day averages, and MACD plus CCI show positive momentum while RSI remains constructive without extreme overbought readings; ADX indicates a modest but present trend. On‑balance volume is positive, confirming buying interest, and pivot levels are beneath the market, reinforcing current strength around 66.12. ATR shows moderate volatility but does not undermine the rally. Technical takeaway: Trend and momentum align in favor of the bulls, with volume confirmation and moving averages supporting the bullish stance.
All signals
  • EMA (5 indicators)$46.55 - $63.18
    Buy
  • RSI (14)66.21
    Neutral
  • Stochastic %K (14, 3, 3)68.95
    Neutral
  • MACD Level (12, 26)2.44
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.